Protein Therapeutics

Covagen AG develops protein-based therapeutics for the treatment of inflammatory diseases and cancer. Its products enable the isolation of high affinity protein-based binders called Fynomers, which changes the activity of target molecules relevant...

Founded in 2007
Total money raised: $87.7M

8057 Y17 M22, Life Science ETH/Uni
Winterthurerstrasse 190


Phone: 41(0)44 635 60 33

Updated on Dec 10, 2013
Covagen at CrunchBase
Jonathan Hepple Non-Executive Director
Karl Nägler Board of Directors
Dr. Anja König Board Positions
Mounia Chaoui Board of Directors

December, 2013

Covagen raised $47.2M in a Series B round from Gimv, Ascent Biomedical Ventures, Novartis Venture Fund, Seroba Kernel, Ventech, MP Healthcare Venture Management, and Edmond de Rothschild Venture Capital

Gimv leads Series B round for Covagen

November, 2010

Covagen raised $6.3M in a Series A round from Seroba Kernel, Edmond de Rothschild Venture Capital, MP Healthcare Venture Management, Novartis Venture Fund, and Ventech

Covagen closes Series A financing round with Seroba Kernel as lead investor

December, 2009

Covagen raised $34.2M in a Series A round from Ventech

Covagen Extends Seed Funds, Plans For $34M Series A

October, 2009

Covagen raised unknown amount in seed round from MP Healthcare Venture Management and Novartis Venture Fund


January, 2007

Covagen was founded on January, 2007